Skip to main content
. 2021 Feb 25;12:1178. doi: 10.1038/s41467-021-21371-5

Fig. 1. Study schema.

Fig. 1

Five men with Type I Fabry disease were infused with autologous transduced CD34+-selected hematopoietic stem/progenitor cells engineered to express α-galactosidase A (α-gal A) following mild ablation. ET enzyme therapy.